|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2006-5-16
|
|
pubmed:abstractText |
It has already been reported that 1-methylnicotinamide (MNA+), a primary metabolite of nicotinamide (vitamin B3), possesses remarkable anti-inflammatory properties [3]. This communication shows that 1-methyl-N'-(hydroxymethyl)nicotinamide (MNAF+ can be regarded as MNA+ precursor able to release simultaneously formaldehyde. Therefore, MNAF+ can be viewed as a candidate for drug with the combined anti-inflammatory and anti-bacterial properties.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1734-1140
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
58
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
246-9
|
|
pubmed:dateRevised |
2008-5-28
|
|
pubmed:meshHeading |
|
|
pubmed:articleTitle |
Search for drugs of the combined anti-inflammatory and anti-bacterial properties: 1-methyl-N'-(hydroxymethyl)nicotinamide.
|
|
pubmed:affiliation |
Chair of Microbiology, Medical University, Hallera 1, PL 90-647 ?ód?, Poland.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
